Galectin Therapeutics Inc. (GALT)

[Amatuer17]

He is focused on the upcoming cohort 3 results of Ketruda combo trial - he is expecting some great results and possible buyout before by MRK before Jun

“It is in its final cohort of dose escalation using double the dosage of the second cohort. Data is due out in June and which is literally only 3 months away and really puts the heat on MRK to buy GALT before the data is released. This data is potentially so robust that it could possibly skip phase 2 and go directly to a quick phase 3 trial with endpoints of a 50% ORR in 6 months. MRK has $8.4 billion versus BMY's $9.3 billion in cash and short-term investments. MRK has proof that GR-MD-02 can double its ORR but BMY has only tried GR-MD-02 in a clinical trial with Yervoy. It's unclear if MRK will want to take a chance that BMY gets the upper hand in the I-O “